SRPT
Sarepta TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case assumes positive program-specific safety/efficacy updates and clearer commercial traction for approved/skilled-access products, pushing multiples toward peer medians and supporting >80% upside vs. anchor.
Posture
Defensive
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bearish as of 2026-06-03.
What can break
Clinical/safety setbacks in gene-therapy programs
Momentum
4
Value
41
Sentiment
100
Setup hits (3d)
1 · Net Bearish
AI TargetsBase $24.00 · Bull $40.00 · Bear $12.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-12 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bearish
Target $20.86
Why
Momentum4 · Δ7d +1.2
Value41 · Δ7d +0.1
Sentiment100 · Δ7d -2.6
So what
Weak posture (Net Bearish). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
4
34% active weight
Current posture
7d trendFlat
Δ7d
+1.2
Δ21d
-37.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendSoftening
Δ7d
-2.6
Δ21d
+23.1
Why this grade
Composite grade D. Momentum 3.9 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.72B
Beta
0.39
Shares Out
104.79M
P/E (TTM) · Derived
-2.3
P/S (TTM)
0.91
P/FCF (TTM) · Derived
-4.60
Rev YoY
-14.5%
EPS YoY
-630.0%
Gross Margin
+76.3%
Op Margin
-11.0%
Net Debt
-$217.67M
Current Ratio
2.95
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology